Table 1.
Selection criteria and patient characteristics
| Author | Inclusion | Exclusion | Patient# | Age (yr) | Sex | Aetiology | Mean LVEF (%)19 | NYHA | Renal function |
|---|---|---|---|---|---|---|---|---|---|
| Ryder et al., 200820 | Weight gain >2 kg in 2 days and symptoms | NA | 107 | 71 ± 11 | 80% male | 70% HFrEF, 30% HFpEF | 38 ± 15 | 8% II 83% III 8% IV | NA |
| Freimark et al., 200921 | Congestion, recent hospitalization | UAP | 190 | 65 ± 12 | 89% male | 77% iCMP | 25 ± 11 | 100% III and IV | Creatinine 1.7 ± 0.7 mg/ml |
| Hebert et al., 201117 | Weight gain >2.2 kg and symptoms | NA | 130 | 58 ± 13 | 73% male | 35% iCMP | 23 ± 10 | 12% I 26% II 29% III 33% IV | eGFR ml/min 70 |
| Lazkani and Ota 201222 | Weight gain >2.2 kg and symptoms | NA | 7 | NA | 57% male | 57% HFrEF, 43% HFpEF | NA | 100% III | NA |
| Banerjee et al., 201223 | Congestion | Advanced chronic kidney disease | 17 | 70 ± 6 | 71% male | 94% HFrEF, 58% iCMP | NA | NA | NA |
| Makadia et al., 201518 | Pulmonary congestion | NA | 106 | 68 ± 13 | 53% male | 64% HFrEF (iCMP), 36% HFpEF | 39 ± 18 | 3% I 44% II 42% III 11% IV | Creatinine 127 micromol/l |
| Buckley et al., 201624 | Pulmonary congestion | Significant acute comorbid condition | 60 | 70 ± 10 | 57% male | 60% HFrEF, 40% HFpEF |
25% in HFrEF 55% in HFpEF |
12% II 58% III 20% IV 10% unknown | Creatinine 115 micromol/l |
| Al‐Ani et al., 201925 | Hypervolemia | NA | 19 | 65 | 57% male | 27% HFrEF | NA | NA | 60% eGFR <60 ml/min |
| Buckley et al., 201926 | Pulmonary congestion | Significant acute comorbid condition | 283 | 68 ± 14 | 62% male | NA | 49% LVEF <40% | NA | NA |
| Zatarain et al., ,201327 | Decompensated heart failure (s.c. Furosemide) | NA | 24 | 75 ± 10 | 79% male | 38% iCMP | 58% LVEF <45% | 93% III and IV | Creatinine 1.59 ± 0.59 mg/ml |
| Gilotra et al., 201828 | Worsening HF (s.c. Furosemide) | Chance of hospitalization | 41 | 57 ± 13 | 78% male | 69%, HFrEF, 33% HFpEF | 25% (range 15‐55%) |
30% II 60% III 10% IV |
eGFR 62 ± 53 ml/min |
EF, ejection fraction; eGFR, estimated glomerular filtration rate; iCMP, ischemic cardiomyopathy; LVEF, left ventricular ejection fraction;NA, not available; NYHA, New York Heart Failure Association; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HT, hypertension; s.c., subcutaneous; UAP, unstable angina pectoris.